Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer

Oncology Letters

Volumn 11, Issue 4, 2016, Pages 2815-2819

  Xu, Mei ^a   Zhang, Bei ^a   Zhang, Meng ^a   Liu, Yang ^a   Yin, Feng Ling ^a   Liu, Xia ^a   Zhuo, Shi Chao ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

B7 H1; B7 H4; Co stimulator; Epithelial ovarian cancer; Neoplasm

Indexed keywords

CA 125 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER STAGING; CELL DIFFERENTIATION; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE RISK; RISK FACTOR; TUMOR VOLUME;

EID: 84960379098     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4301     Document Type: Article

References (19)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Varughese E, Kondalsamy-Chennakesavan S and Obermair A: The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: A retrospective study. J Ovarian Res 5: 11, 2012.
3. Givens V, Mitchell GE, Harraway-Smith C, Reddy A and Maness DL: Diagnosis and management of adnexal masses. Am Fam Physician 80: 815-820, 2009.
4. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE and Urban N: Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 125: 65-69, 2012.
5. He C, Qiao H, Jiang H and Sun X: The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol 2011: 695834, 2011.
6. Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R and Tao M: B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 6: 3452-3461, 2015.
7. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F and Gai XD: B7-H1 and B7-H4 expression in colorectal carcinoma: Correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 116: 1163-1168, 2014.
8. Topalian SL, Drake CG and Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24: 207-212, 2012.
9. Wang X, Wang T, Xu M, Xiao L, Luo Y, Huang W, Zhang Y and Geng W: B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas. Hum Immunol 75: 1203-1209, 2014.
10. Song X, Liu J, Lu Y, Jin H and Huang D: Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol Rep 31: 1191-1198, 2014.
11. Yu XW, Li CH, Zhang SL, et al: Study on the expression of PD-L1 in patients with ovarian cancer. Chin J Lab Diagn 14: 1854-1856, 2010.
12. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and Xu N: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108: 19-24, 2006.
13. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104: 3360-3365, 2007.
14. Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G and Papkoff J: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306: 128-141, 2005.
15. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J and Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100: 44-52, 2006.
16. Zhang N, Fang P and Gu ZJ: Preparation and characterization of monoclonal antibody against human B7-H4 molecule. Monoclon Antib Immunodiagn Immunother 33: 270-274, 2014.
17. Sznol M: Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J 20: 290-295, 2014.
18. Afreen S and Dermime S: The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol Oncol Stem Cell Ther 7: 1-17, 2014.
19. Qian Y, Hong B, Shen L, Wu Z, Yao H and Zhang L: B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res 353: 139-151, 2013.